Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.74 |
| ▸ | LCK | P06239 | 6/20 | 0.74 |
| ▸ | EGFR | P00533 | 4/20 | 0.74 |
| ▸ | BTK | Q06187 | 4/20 | 0.57 |
| ▸ | JAK2 | O60674 | 7/20 | 0.42 |
| ▸ | JAK1 | P23458 | 7/20 | 0.42 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31039916 | 0.86 | JAK3 (0.60) | JAK3LCKEGFRBTKJAK2 | |
| SCHEMBL21946882 | 0.86 | JAK3 (0.60) | JAK3LCKEGFRBTKJAK2 | |
| SCHEMBL21946316 | 0.86 | JAK3 (0.60) | JAK3LCKEGFRBTKJAK2 | |
| SCHEMBL24927487 | 0.86 | JAK3 (0.60) | JAK3LCKEGFRBTKJAK2 | |
| SCHEMBL27175833 | 0.86 | JAK3 (0.73) | JAK3LCKEGFRBTK | |
| SCHEMBL30160965 | 0.86 | JAK3 (0.73) | JAK3LCKEGFRBTK | |
| SCHEMBL16764140 | 0.86 | JAK3 (1.00) | JAK3LCKEGFRBTK | |
| SCHEMBL16764138 | 0.86 | JAK3 (1.00) | JAK3LCKEGFRBTK | |
| SCHEMBL24926138 | 0.85 | JAK3 (0.79) | JAK3LCKEGFRBTK | |
| SCHEMBL21946354 | 0.85 | JAK3 (0.56) | JAK3LCKEGFRBTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | JAK3 53/4885LCK 3/4885EGFR 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.